Despite its potential, targeting STAT3 poses several challenges:
Lack of specificity: Many small molecule inhibitors affect other signaling pathways, leading to off-target effects. Drug resistance: Cancer cells can develop resistance to STAT3 inhibitors through compensatory pathways or mutations. Delivery issues: Efficient delivery of oligonucleotide-based therapeutics remains a significant hurdle.
